Clovis Oncology reviews net loss of $15 femme pharmacie.

Clovis Oncology reviews net loss of $15 femme pharmacie .7 million for second quarter 2012 Clovis Oncology, Inc. today reported financial results for the second one fourth 2012, and supplied an update on the progress of its clinical development programs and expected milestones for all of those other year. Mahaffy, CEO and President of Clovis Oncology. ‘We are seeking to broaden our pipeline through our collaboration with Array BioPharma for the discovery of a novel mutant KIT inhibitor; each of our three current clinical applications continues to advance, and most importantly, we stick to track to announce the results from our pivotal LEAP trial of CO-101 in metastatic pancreatic cancer through the fourth quarter this year.’ 2012 Financial Outcomes and Outlook Clovis reported a net lack of $15.7 million for the second quarter of 2012, and $34.7 million for the first fifty % of 2012.

sildénafil

This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.. Coalition announces 2011 Little Grants Program for World Pneumonia Day The Global Coalition against Kid Pneumonia announced the Globe Pneumonia Day 2011 Little Grants Program recently, aimed at funding innovative occasions and actions on or around World Pneumonia Day that address gaps in avoidance and control of the condition, according to a news release.